Home|Best-Bschool-in-india-2018

DSIJ Mindshare

Understanding Value at Risk (VaR) Margin & Extreme Loss Margin (ELM) in the Stock Market Understanding Value at Risk (VaR) Margin & Extreme Loss Margin (ELM) in the Stock Market

Understanding Value at Risk (VaR) Margin & Extreme Loss Margin (ELM) in the Stock Market

Investors and traders are always concerned about the potential losses they may face, and risk management techniques are used to help minimize these losses.

Kiran Shroff 0 109 Article rating: 5.0

Two important concepts that help with this are the Value at Risk (VaR) Margin and Extreme Loss Margin (ELM).

Read more
Debt-Free EPC Company Bags New Orders Worth Rs 22,05,00,000 From Reliance Mappedu Multi Modal Logistics Park & Komatsu India Debt-Free EPC Company Bags New Orders Worth Rs 22,05,00,000 From Reliance Mappedu Multi Modal Logistics Park & Komatsu India

Debt-Free EPC Company Bags New Orders Worth Rs 22,05,00,000 From Reliance Mappedu Multi Modal Logistics Park & Komatsu India

The company has a market cap of over Rs 1,100 crore and as of September 2024, it is debt-free.

Kiran Shroff 0 333 Article rating: 4.4

The shares of the company have an ROE of 95 per cent and an ROCE of 117 per cent.

Read more
US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

Abhishek Wani 0 170 Article rating: 5.0

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

Read more
Stocks in Focus: Bangalore-based Small Finance Bank Approved to Sell Its Non-Performing Assets (NPA) and Written-Off Loans, Stock Closed 1.17 Per Cent Lower Stocks in Focus: Bangalore-based Small Finance Bank Approved to Sell Its Non-Performing Assets (NPA) and Written-Off Loans, Stock Closed 1.17 Per Cent Lower

Stocks in Focus: Bangalore-based Small Finance Bank Approved to Sell Its Non-Performing Assets (NPA) and Written-Off Loans, Stock Closed 1.17 Per Cent Lower

Small Finance Bank Shares in Focus After Approval to Sell Rs 364.51 Crore Micro Banking Loan Pool

Abhishek Wani 0 98 Article rating: 5.0

Small Finance Bank Shares in Focus After Approval to Sell Rs 364.51 Crore Micro Banking Loan Pool

Read more
RSS
First105106107108110112113114Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual
BSE Enlistment No. 5307

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual
BSE Enlistment No. 1346

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Conditions | Privacy Statement | WhiteList